Morris Heather, DeWolf Susan, Robins Harlan, Sprangers Ben, LoCascio Samuel A, Shonts Brittany A, Kawai Tatsuo, Wong Waichi, Yang Suxiao, Zuber Julien, Shen Yufeng, Sykes Megan
Columbia University Medical Center, New York, NY 10032, USA.
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Sci Transl Med. 2015 Jan 28;7(272):272ra10. doi: 10.1126/scitranslmed.3010760.
T cell responses to allogeneic major histocompatibility complex antigens present a formidable barrier to organ transplantation, necessitating long-term immunosuppression to minimize rejection. Chronic rejection and drug-induced morbidities are major limitations that could be overcome by allograft tolerance induction. Tolerance was first intentionally induced in humans via combined kidney and bone marrow transplantation (CKBMT), but the mechanisms of tolerance in these patients are incompletely understood. We now establish an assay to identify donor-reactive T cells and test the role of deletion in tolerance after CKBMT. Using high-throughput sequencing of the T cell receptor B chain CDR3 region, we define a fingerprint of the donor-reactive T cell repertoire before transplantation and track those clones after transplant. We observed posttransplant reductions in donor-reactive T cell clones in three tolerant CKBMT patients; such reductions were not observed in a fourth, nontolerant, CKBMT patient or in two conventional kidney transplant recipients on standard immunosuppressive regimens. T cell repertoire turnover due to lymphocyte-depleting conditioning only partially accounted for the observed reductions in tolerant patients; in fact, conventional transplant recipients showed expansion of circulating donor-reactive clones, despite extensive repertoire turnover. Moreover, loss of donor-reactive T cell clones more closely associated with tolerance induction than in vitro functional assays. Our analysis supports clonal deletion as a mechanism of allograft tolerance in CKBMT patients. The results validate the contribution of donor-reactive T cell clones identified before transplant by our method, supporting further exploration as a potential biomarker of transplant outcomes.
T细胞对同种异体主要组织相容性复合体抗原的反应是器官移植的一个巨大障碍,因此需要长期免疫抑制以尽量减少排斥反应。慢性排斥反应和药物引起的并发症是主要限制因素,而异体移植耐受诱导可克服这些问题。耐受性最初是通过联合肾脏和骨髓移植(CKBMT)在人类中有意诱导的,但这些患者的耐受机制尚未完全了解。我们现在建立了一种检测方法来识别供体反应性T细胞,并测试CKBMT后缺失在耐受中的作用。通过对T细胞受体β链CDR3区域进行高通量测序,我们定义了移植前供体反应性T细胞库的特征,并在移植后追踪这些克隆。我们观察到三名耐受的CKBMT患者移植后供体反应性T细胞克隆减少;在第四名非耐受的CKBMT患者或两名接受标准免疫抑制方案的传统肾移植受者中未观察到这种减少。由于淋巴细胞清除预处理导致的T细胞库更新仅部分解释了耐受患者中观察到的减少;事实上,传统移植受者尽管T细胞库有广泛更新,但循环供体反应性克隆却出现扩增。此外,供体反应性T细胞克隆的丢失与耐受诱导的相关性比体外功能检测更密切。我们的分析支持克隆缺失是CKBMT患者异体移植耐受的一种机制。结果验证了我们的方法在移植前鉴定的供体反应性T细胞克隆的作用,支持进一步探索将其作为移植结果的潜在生物标志物。